Subacute cutaneous lupus erythematosus associated with leflunomide

Cutis

Volumn 76, Issue 3, 2005, Pages 189-192

  Elias, Anthony R ^a,b   Tam, Christine C ^b   David Bajar, Kathleen M ^b  

^a Army Medical Department Center and School   (United States)

^b Department of Dermatology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOXAZOLE DERIVATIVE; LEFLUNOMIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; MIDDLE AGED; REVIEW; RHEUMATOID ARTHRITIS; SKIN LUPUS ERYTHEMATOSUS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; ISOXAZOLES; LUPUS ERYTHEMATOSUS, CUTANEOUS; MIDDLE AGED;

EID: 26244468926     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Strand V, Cohen S, Schiff M, et al, for the Leflunomide Rheumatoid Arthritis Investigators Group. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med. 1999;159:2542-2550.
2. Williams JW, Mital D, Chong A, et al. Experiences with leflunomide in solid organ transplantation. Transplantation. 2002;73:358-366.
3. Mrowka C, Thoenes GH, Langer KH, et al. Prevention of the acute graft-versus-host disease (GVHD) in rats by the immunomodulating drug leflunomide. Ann Hematol. 1994;68:195-199.
4. Eckhardt SG, Rizzo J, Sweeney KR, et al. Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol. 1999;17:1095-1104.
5. Wallace DJ. Management of lupus erythematosus: recent insights. Curr Opin Rheumatol. 2002;14:212-219.
6. Nousari HC, Anhalt GJ. Bullous pemphigoid treated with leflunomide: a novel immunomodulatory agent. Arch Dermatol. 2000;136:1204-1205.
7. Reich K, Hummel KM, Beckmann I, et al. Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Br J Dermatol. 2002;146:335-336.
8. Arava [package insert]. Kansas City, Mo: Aventis Pharmaceuticals, Inc; 2000.
9. Chong AS, Rezai K, Gebel HM, et al. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation. 1996;61:140-145.
10. Siemasko KF, Chong AS, Williams JW, et al. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation. 1996;61:635-642.
11. Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999;93:198-208.
12. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol. 2000;165:5962-5969.
13. Holm EA, Balslev E, Jemec GB. Vasculitis occurring during leflunomide therapy. Dermatology. 2001;203:258-259.
14. David-Bajar KM. Subacute cutaneous lupus erythematosus. J Invest Dermatol. 1993;100:2S-8S.
15. Lipsker D, Di Cesare MP, Cribier B, et al. The significance of the 'dust-like particles' pattern of immunofluorescence. a study of 66 cases. Br J Dermatol. 1998;138:1039-1042.
16. Leroy D, Dompmartin A, Le Jean S, et al. Dermatitis caused by aldactone of a lupic annular erythema type [in French]. Ann Dermatol Venereol. 1987;114:1237-1240.
17. Fernandez-Diaz ML, Herranz P, Suarez-Marrero MC, et al. Subacute cutaneous lupus erythematosus associated with cilazapril [letter]. Lancet. 1995;345:398.
18. Crowson AN, Magro CM. Lichenoid and subacute cutaneous lupus erythematosus-like dermatitis associated with antihistamine therapy. J Cutan Pathol. 1999;26:95-99.
19. Crowson AN, Magro CM. Subacute cutaneous lupus erythematosus arising in the setting of calcium channel blocker therapy. Hum Pathol. 1997;28:67-73.
20. Toll A, Campo-Pisa P, Gonzalez-Castro J, et al. Subacute cutaneous lupus erythematosus associated with cinnarizine and thiethylperazine therapy. Lupus. 1998;7:364-366.
21. Bleumink GS, ter Borg EJ, Ramselaar CG, et al. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford). 2001;40:1317-1319.
22. Sontheimer RD. Subacute cutaneous lupus erythematosus: a decade's perspective. Med Clin North Am. 1989;73:1073-1090.
23. Balsa A, Bernad M, de Miguel E, et al. Subacute cutaneous lupus erythematosus caused by chrysotherapy in rheumatoid arthritis [in Spanish]. Rev Clin Esp. 1988;182:505-506.
24. Miyagawa S, Okuchi T, Shiomi Y, et al. Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin. J Am Acad Dermatol. 1989;21:343-346.
25. Nousari HC, Kimyai-Asadi A, Tausk FA. Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet. 1998;352:1825-1826.
26. Parodi A, Rivara G, Guarrera M. Possible naproxen-induced relapse of subacute cutaneous lupus erythematosus. JAMA. 1992;268:51-52.
27. Ross S, Ormerod AD, Roberts C, et al. Subacute cutaneous lupus erythematosus associated with phenytoin. Clin Exp Dermatol. 2002;27:474-476.
28. Roura M, Lopez-Gil F, Umbert P. Systemic lupus erythematosus exacerbated by piroxicam. Dermatologica. 1991;182:56-58.
29. McGrath H Jr, Scopelitis E, Nesbitt LT Jr. Subacute cutaneous lupus erythematosus during psoralen ultraviolet A therapy. Arthritis Rheum. 1990;33:302-303.
30. Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch Dermatol. 2001;137:1196-1198.
31. Callen JP. Drug-induced cutaneous lupus erythematosus, a distinct syndrome that is frequently unrecognized. J Am Acad Dermatol. 2001;45:315-316.
32. Norris DA. Pathomechanisms of photosensitive lupus erythematosus. J Invest Dermatol. 1993;100:58S-68S.
33. Fautrel B, Foltz V, Frances C, et al. Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al. Arthritis Rheum. 2002;46:1408-1409.